Orphan Drug Status


In January 2017, the European Commission followed the recommendation from the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) to approve Hansa Medical’s application for Orphan Drug Designation of recombinant IdeS for the prevention of graft rejection following solid organ transplantation. In September 2015, IdeS was granted Orphan Drug Designation for the prevention of antibody mediated organ rejection in solid organ transplant patients by the U.S. Food and Drug Administration (FDA).

Orphan Drug Designation is granted to drugs intended for the treatment of life threatening or chronically debilitating rare diseases where no therapeutic options are either authorized or where the drugs will be of significant benefit to those affected by the condition. Rare diseases are those de ned as having a prevalence of no more than five in 10,000 persons in Europe or affecting less than 200,000 patients in the US. The designation provides development and commercial incentives, including 10 years of market exclusivity in the EU and 7 years in the US, protocol assistance on the development of the drug, including clinical studies and certain exemptions from or reductions in regulatory fees.